Capital Investment Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Capital Investment Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,737	Closed	-$218K	–	613
2021 Q3	$218K	Sell	1,737 -236	-12%	-$30.4K	0.01%	523
2021 Q2	$267K	Sell	1,973 -20	-1%	-$2.63K	0.01%	483
2021 Q1	$270K	Hold	1,993	–	–	0.01%	456
2020 Q4	$281K	Buy	1,993 +33	+2%	+$4.23K	0.01%	433
2020 Q3	$218K	Buy	+1,960	New	+$220K	0.01%	458

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Capital Investment Advisors's XBI Position: Q4 2021 in Review

Capital Investment Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2021, closing a stake of 1,737 shares — an estimated $218K sold.

Capital Investment Advisors first reported a position in XBI in Q3 2020 and held it in 5 quarters. The position peaked at $281K in Q4 2020. 702 funds tracked by Wall St. Rank hold XBI as of Q4 2021.

Capital Investment Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2021 after selling out during the quarter.
Capital Investment Advisors sold 1,737 State Street SPDR S&P Biotech ETF shares in Q4 2021, an estimated $218K.
Capital Investment Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and held it in 5 quarters.
Capital Investment Advisors's State Street SPDR S&P Biotech ETF position peaked at $281K in Q4 2020.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2021.

Based on Capital Investment Advisors's 13F filing for Q4 2021, filed 10 Jan 2022.